Literature DB >> 10425406

Durability of new squamous epithelium after endoscopic reversal of Barrett's esophagus.

P Sharma1, A Bhattacharyya, H S Garewal, R E Sampliner.   

Abstract

BACKGROUND: Endoscopic reversal of Barrett's esophagus with multipolar electrocoagulation and high-dose omeprazole has been previously described but long-term results are not available. The aim of this study was to follow patients after endoscopic reversal and to perform a detailed analysis of the "new" squamous mucosa.
METHODS: After reversal, patients with Barrett's esophagus were maintained on high-dose omeprazole and underwent interval endoscopy, and large biopsies were obtained of the former Barrett's epithelium.
RESULTS: Nine of 11 patients were men; the mean age was 62 years. The mean length of Barrett's mucosa was 4.4 cm; the mean dose of omeprazole used was 49 mg/day. All patients had an initial complete response to treatment-no evidence of Barrett's endoscopically and histologically. Three patients had intestinal metaplasia underlying the new squamous mucosa in the latest follow-up biopsies. In these 3 patients, only 0.4%, 2%, and 8% of the total biopsy area had intestinal metaplasia. All but 4 patients had underlying intestinal metaplasia at variable times during the study period. Patients have been followed for a mean of 36 months (range 19 to 53 months).
CONCLUSIONS: New squamous mucosa is durable and resembles normal squamous tissue. Underlying glands of intestinal metaplasia are intermittently found. Because the significance of this residual intestinal metaplasia is unclear, surveillance endoscopy with biopsies of the treated segment is recommended even after reversal therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10425406     DOI: 10.1016/s0016-5107(99)70218-x

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  14 in total

Review 1.  Reversal of Barrett's esophagus with electrocoagulation and laser.

Authors:  R E Sampliner
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

2.  [Barrett esophagus: ablative methods of treatment].

Authors:  M Jung; C Ell
Journal:  Internist (Berl)       Date:  2003-01       Impact factor: 0.743

3.  Ablative mucosectomy is the procedure of choice to prevent Barrett's cancer.

Authors:  R C Fitzgerald
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 4.  Current status of ablative therapies in esophageal disorders.

Authors:  P Sharma
Journal:  Curr Gastroenterol Rep       Date:  2001-06

Review 5.  Biopsy assessment of drug efficacy in the gastrointestinal tract.

Authors:  Marjorie M Walker
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

6.  Barrett's esophagus: endoscopic treatments II.

Authors:  Bruce D Greenwald; Charles J Lightdale; Julian A Abrams; John D Horwhat; Ram Chuttani; Srinadh Komanduri; Melissa P Upton; Henry D Appelman; Helen M Shields; Nicholas J Shaheen; Stephen J Sontag
Journal:  Ann N Y Acad Sci       Date:  2011-09       Impact factor: 5.691

Review 7.  A systematic review and meta-analysis of the treatment for Barrett's esophagus.

Authors:  You-Ming Li; Lan Li; Chao-Hui Yu; You-Shi Liu; Cheng-Fu Xu
Journal:  Dig Dis Sci       Date:  2008-04-22       Impact factor: 3.199

Review 8.  Ablative therapies for Barrett's esophagus.

Authors:  Katherine S Garman; Nicholas J Shaheen
Journal:  Curr Gastroenterol Rep       Date:  2011-06

9.  Carcinogenesis of Barrett's esophagus: a review of the clinical literature.

Authors:  Jiro Watari; Tadayuki Oshima; Hirokazu Fukui; Toshihiko Tomita; Hiroto Miwa
Journal:  Clin J Gastroenterol       Date:  2013-08-14

10.  Histology assessment of bipolar coagulation and argon plasma coagulation on digestive tract.

Authors:  Teresa Garrido; Elisa R Baba; Stephanie Wodak; Paulo Sakai; Ivan Cecconello; Fauze Maluf-Filho
Journal:  World J Gastrointest Endosc       Date:  2014-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.